30.01.2018 • News

EU Extends Bayer-Monsanto Deadline

Bayer’s proposed acquisition of Monsanto faces another delay after European...
Bayer’s proposed acquisition of Monsanto faces another delay after European regulators extended their investigation by five days to Mar. 12. (c) Bayer

Bayer’s proposed acquisition of Monsanto faces another delay after European regulators extended their investigation by five days to Mar. 12.

The European Commission has not given a reason for the extension, which effectively gives the German group a new deadline of midnight on Feb. 5 to propose further concessions. The deadline has already been extended once after the Commission opened an in-depth review of the merger last August.

Bayer has already committed to sell certain crop science businesses to German rival BASF for €5.9 billion but is said to be bracing itself for antitrust authorities to require further asset sales.

India also raised its concerns on the merger earlier this month. The Competition Commission of India (CCI) said that Bayer’s proposed buyout of Monsanto would adversely hit competitors’ operations. Consequently, the antitrust authority launched a public consultation on Jan. 5.

However, according to reports in the Indian media, Bayer said it was still confident of getting approval from the CCI, hopefully by April/May.

The deal is now valued at $63.5 billion including debt, which is $2.5 billion less than the initial price tag of $66 billion after Monsanto lowered its financial liabilities last October.

If it goes ahead, the transaction would make Bayer the world’s largest supplier of seeds and agrochemicals, surpassing ChemChina, which acquired Syngenta last year, DowDuPont and BASF.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read